JNJ 64164711
Alternative Names: JNJ 711; JNJ-64164711Latest Information Update: 28 May 2022
At a glance
- Originator Janssen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte inhibitors; TNFRSF18 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 21 Apr 2018 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 01 Apr 2018 Preclinical trials in Solid tumours in USA (unspecified route), before April 2018